BioLife Solutions, Inc. <BLFS.O>: Benchmark cuts to hold rating
BLFS•Related News
Silence Therapeutics says Phase 2 SANRECO trial meets primary endpoint for divesiran in polycythemia vera
SLN•
Marex agrees to buy Netherlands-based Brainchild Capital Investments
MRX•
Silicon Motion plans $800 million zero-coupon convertible senior notes offering due 2031
SIMO•
3D Systems wins additional $9 million U.S. Air Force contract for large-format metal 3D printer program
DDD•
Interface, Inc. <TILE.O>: Barrington Research Raises Target Price to $45 From $36
TILE•